Home Abstract

Formulation and Evaluation of Eudragit RS100 Nanoparticles

Received On: 19/11/2014
Accepted On: 27/11/2014


Patel, C. J., Patel, D. V.

Author's Affiliation


The Glibenclamide is a drug of choice for the physician for Non-Insulin Dependent Diabetes (NIDD). The drug in oral conventional dosage form has the dosage regime of three times a day. The repeated administration in a day may cause noncompliance by the patients. Thus, it is emphasized to prolong/sustain release delivery of the drug to avoid repeated administration. The objective of the present study was to develop Glibenclamide loaded nanoparticles using Eudragit RS100 as release control polymer. Different ratio of Drug: Eudragit RS100 was tried. The prepared nanoparticles were evaluated for particle size, zeta potential, % yield, Association efficiency, CPR. In-vivo anti-hyperglycemic activity of the FN8 batch was studied. The formulation containing 1:4 ratio of Drug:Eudragit RS100 was selected as best formulation.


Glibenclamide, Eudragit RS100, Nanoparticle, Factorial Design, Optimization

Cite This Article

Patel, C. J., & Patel, D. V. (2014). Formulation and Evaluation of Eudragit RS100 Nanoparticles Containing Glibenclamide, International Journal for Pharmaceutical Research Scholars (IJPRS), 3(4), 165-173.

Recent Articles

Get FREE Updates for Upcoming
Pharma News, Jobs & Conferences

You have successfully subscribed to the newsletter

There was an error while trying to send your request. Please try again.

IJPRS will use the information you provide on this form to be in touch with you and to provide updates and marketing.